(S)-toluene-4-sulfonic acid 3-hydroxy-hexyl ester | 143617-62-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-toluene-4-sulfonic acid 3-hydroxy-hexyl ester
• 英文别名: [(3S)-3-hydroxyhexyl] 4-methylbenzenesulfonate
• CAS: 143617-62-3
• 化学式: C₁₃H₂₀O₄S
• 分子量: 272.365
• InChiKey: QSYANYPKPQOLEE-LBPRGKRZSA-N

物化性质

• 沸点：
  426.5±28.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-toluene-4-sulfonic acid 3-hydroxy-hexyl ester 在 sodium azide 、 二甲基硫 、 二异丁基氢化铝 、 臭氧 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 乙醚 为溶剂， 反应 17.25h， 生成 rel-(2R,6R)-2-(3-hydroxyheptyl)-6-propylpiperidine
  参考文献：
  名称：

  Enantioselective ruthenium-mediated synthesis of (-)-indolizidine 223AB

  摘要：

  Triphenylphosphine/CCl4-mediated cyclization of amino alcohol 17 proceeded smoothly, with single inversion, to provide (-)-indolizidine 223AB 4. Amino alcohol 17 was prepared by thermolysis of azide 16, followed by DIBAL reduction of the intermediate imine. Symchiral aldehyde 12 and phosphonium salt 15, precursors to 16, were prepared by BINAP.Ru*-mediated hydrogenation of the corresponding beta-keto esters. A simplified procedure allows this hydrogenation to be carried out in a Parr shaker, at 80-degrees-C and 50 psig of H-2.

  DOI：

  10.1021/jo00048a037
• 作为产物：
  描述：

  S-3-hydroxyhexanoic Acid methyl ester 在 吡啶 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 (S)-toluene-4-sulfonic acid 3-hydroxy-hexyl ester
  参考文献：
  名称：

  Enantioselective ruthenium-mediated synthesis of (-)-indolizidine 223AB

  摘要：

  Triphenylphosphine/CCl4-mediated cyclization of amino alcohol 17 proceeded smoothly, with single inversion, to provide (-)-indolizidine 223AB 4. Amino alcohol 17 was prepared by thermolysis of azide 16, followed by DIBAL reduction of the intermediate imine. Symchiral aldehyde 12 and phosphonium salt 15, precursors to 16, were prepared by BINAP.Ru*-mediated hydrogenation of the corresponding beta-keto esters. A simplified procedure allows this hydrogenation to be carried out in a Parr shaker, at 80-degrees-C and 50 psig of H-2.

  DOI：

  10.1021/jo00048a037

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005092835A1

  公开（公告）日：2005-10-06

  The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from -O- and -S-; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from phenyl, pyrrolidinyl, piperidinyl, morpholinyl, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from (a), (b), (c), (d), (e), (f) where R3, R4 and R5 are independently selected from hydrogen, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R6 and R7 are independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R8 is selected from chloro, bromo, iodo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R1 and R2 are each independently hydrogen or C1-C4 alkyl; or pharmaceutically acceptable salts thereof; or compositions thereof and methods of using the same.

  本发明涉及5-羟色胺和/或去甲肾上腺素再摄取的抑制剂，具体提供了如下公式(I)的化合物：其中A选自-O-和-S-；X选自C1-C8烷基，C2-C8烯基和C4-C8环烷基烷基，其中每个基团可任选地被最多3个独立选自苯基、吡咯烷基、哌啶基、吗啉基、卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团取代，其中n为0、1或2，-CF3，-CN和-CONH2；Y选自(a)，(b)，(c)，(d)，(e)，(f)，其中R3、R4和R5独立选自氢、卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、-CF3，-SCF3和腈；R6和R7独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、-CF3，-SCF3和腈；R8选自氯、溴、碘、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、-CF3，-SCF3和腈；R1和R2各自独立地为氢或C1-C4烷基；或其药用可接受的盐；或其组合物及使用方法。
• Pharmaceutical compounds
  申请人：Boulet Louis Serge

  公开号：US20070072859A1

  公开（公告）日：2007-03-29

  The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from —O— and —S—; X is selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, and C 4 -C 8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from phenyl, pyrrolidinyl, piperidinyl, morpholinyl, halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2, —CF 3 , —CN and —CONH 2 ; Y is selected from (a), (b), (c), (d), (e), (f) where R 3 , R 4 and R 5 are independently selected from hydrogen, halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2, nitro, acetyl, —CF 3 , —SCF 3 and cyano; R 6 and R 7 are independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2, nitro, acetyl, —CF 3 , —SCF 3 and cyano; R 8 is selected from chloro, bromo, iodo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2, nitro, acetyl, —CF 3 , —SCF 3 and cyano; R 1 and R 2 are each independently hydrogen or C 1 -C 4 alkyl; or pharmaceutically acceptable salts thereof; or compositions thereof and methods of using the same.

  本发明涉及抑制血清素和/或去甲肾上腺素再摄取的抑制剂，具体提供了式（I）的化合物：其中A选自- O-和- S-; X选自C1-C8烷基，C2-C8烯基和C4-C8环烷基烷基，每个基团都可以选择性地被取代，每个基团独立地选自苯基，吡咯烷基，哌啶基，吗啉基，卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0、1或2，-CF3，-CN和-CONH2; Y选自（a），（b），（c），（d），（e），（f），其中R3，R4和R5独立地选自氢，卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0、1或2，硝基，乙酰，-CF3，-SCF3和氰基; R6和R7独立地选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0、1或2，硝基，乙酰，-CF3，-SCF3和氰基; R8选自氯，溴，碘，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0、1或2，硝基，乙酰，-CF3，-SCF3和氰基; R1和R2各自独立地为氢或C1-C4烷基; 或其药学上可接受的盐; 或其组合物和使用方法。
• Enantioselective ruthenium-mediated synthesis of (-)-indolizidine 223AB
  作者：Douglass F. Taber、P. Bruce Deker、Lee J. Silverberg

  DOI：10.1021/jo00048a037

  日期：1992.10

  Triphenylphosphine/CCl4-mediated cyclization of amino alcohol 17 proceeded smoothly, with single inversion, to provide (-)-indolizidine 223AB 4. Amino alcohol 17 was prepared by thermolysis of azide 16, followed by DIBAL reduction of the intermediate imine. Symchiral aldehyde 12 and phosphonium salt 15, precursors to 16, were prepared by BINAP.Ru*-mediated hydrogenation of the corresponding beta-keto esters. A simplified procedure allows this hydrogenation to be carried out in a Parr shaker, at 80-degrees-C and 50 psig of H-2.